Research summaries for everyoneNot medical advice

Elevated Pharma · Research & evidence

Research, in context.

Explore 24 references across 8 research areas. Each brings together key studies, current FDA status, evidence limits and the original sources. Updated November 7, 2026.

What do the evidence labels mean?

The label describes the sources in each reference. Open a record to read the evidence limits and follow the original links.

Clinical or human research
Research involving people. Findings belong to the substance, population and study described.
Preclinical literature
Cell, laboratory or animal research. This is a different evidence level from human research.
Drug or biologic labeling
Published labeling for a particular regulated product. That status belongs to that product.
Biochemical or analytical reference
Information about identity, composition or analysis. It does not establish a personal outcome.
Component sources only
Sources concern individual ingredients. The blend itself has no combined evidence conclusion assigned here.
Identity review required
The material name leaves a composition or identity question that needs documentation.
How we assess a source →

Research summaries & sources

24 references shown

RetatrutideTriple-receptor research · GLP-1, GIP & glucagonPhase 3 clinical research 10 key studiesResearch & sources

Retatrutide is an investigational peptide studied at the GLP-1, GIP and glucagon receptors. Phase 3 trials have been reporting since May 2026, and the sponsor plans to file for FDA approval in early 2027.

Research summary
Published phase 3 trials now include TRIUMPH-1 (NEJM, 2026), TRIUMPH-2 and TRANSCEND-T2D-1 (Lancet, 2026), alongside the 2023 phase 2 trial. Sponsor-reported results add TRIUMPH-3, TRIUMPH-4 and a head-to-head comparison with semaglutide.
Evidence limits
Trial results describe the sponsor’s investigational drug in the studied populations. They do not establish the identity, quality or safety of any independently sourced material.
U.S. status · November 7, 2026
Investigational. Lilly states retatrutide is legally available only to participants in its clinical trials and plans to submit it for FDA review in the first quarter of 2027.
Read the full Retatrutide reference →Send research request →
Identity & technical details
Primary name
Retatrutide
Also indexed as
LY3437943
TirzepatideDual-receptor research · GLP-1 & GIPFDA-labeled drug reference 9 key studiesResearch & sources

Tirzepatide is a dual GIP and GLP-1 receptor agonist and the active ingredient in two FDA-approved medicines, Mounjaro and Zepbound. Its trial record is one of the largest of any peptide in this library.

Research summary
The SURPASS (type 2 diabetes) and SURMOUNT (obesity) phase 3 programs are published, including head-to-head trials against semaglutide, a weight-maintenance trial and a three-year diabetes-prevention analysis.
Evidence limits
Approval and trial results apply to the approved products as labeled. They do not transfer to an unlabeled research material or another supplier’s product.
U.S. status · November 7, 2026
FDA-approved as Mounjaro (type 2 diabetes, including children 10 and older since late 2025) and Zepbound (chronic weight management and obstructive sleep apnea). FDA approved a multi-dose Zepbound KwikPen in February 2026.
Read the full Tirzepatide reference →Send research request →
Identity & technical details
Primary name
Tirzepatide
Also indexed as
LY3298176
Molecular formula
C225H348N48O68
Molecular mass
4813 g/mol
PubChem CID
166567236

Key studies

AOD9604Growth-hormone fragment · Metabolic researchPreclinical literature / FDA review 4 key studiesResearch & sources

AOD9604 is a modified fragment of the C-terminal end of human growth hormone, studied in mouse metabolic models and in early human obesity trials that did not lead to approval.

Research summary
Published work includes mouse fat-metabolism studies, a rabbit joint model and doping-detection methods.
Evidence limits
Mouse findings do not establish human effectiveness or safety.
U.S. status · November 7, 2026
Not FDA-approved. FDA has cited insufficient safety information for compounded AOD-9604.
Read the full AOD9604 reference →Send research request →
Identity & technical details
Primary name
AOD9604
Also indexed as
AOD-9604 / Modified growth hormone C-terminal fragment
Molecular formula
C78H123N23O23S2
Molecular mass
1815.1 g/mol
PubChem CID
71300630
5-Amino-1MQSmall molecule · Cellular metabolism researchPreclinical literature 4 key studiesResearch & sources

5-Amino-1MQ is a small-molecule inhibitor of the enzyme NNMT, not a peptide. Its published record is small and preclinical.

Research summary
Enzyme, cell and mouse studies of NNMT inhibition, plus a rat pharmacokinetic method paper. No human trial was found.
Evidence limits
The free cation and the iodide salt have different formulas and masses and are not interchangeable.
U.S. status · November 7, 2026
Not FDA-approved. No human safety conclusion or permitted-use claim is made.
Read the full 5-Amino-1MQ reference →Send research request →
Identity & technical details
Primary name
5-Amino-1MQ
Also indexed as
5-Amino-1-methylquinolinium / 5-Amino-1-methylquinolinium iodide
Molecular formula
C10H11IN2
Molecular mass
286.11 g/mol
PubChem CID
66522933
GHK-CuCopper peptide · Skin researchPreclinical literature 6 key studiesResearch & sources

GHK-Cu is the copper complex of the tripeptide glycyl-histidyl-lysine. It is widely studied in skin and wound models and used in topical cosmetics.

Research summary
Evidence includes laboratory and animal wound studies, gene-expression work and small topical human studies. A 2026 review focuses on copper speciation and formulation quality.
Evidence limits
Preclinical findings do not establish clinical benefit, and topical findings do not transfer to injected material.
U.S. status · November 7, 2026
FDA removed injectable GHK-Cu from its Category 2 compounding list in April 2026 and scheduled it for advisory-committee review before the end of February 2027. It is not covered by the October 2026 HHS interim policy.
Read the full GHK-Cu reference →Send research request →
Identity & technical details
Primary name
GHK-Cu
Also indexed as
Copper tripeptide-1 / Copper glycyl-L-histidyl-L-lysine
Sequence
Gly-His-Lys
Molecular formula
C14H21CuN6O4-
Molecular mass
400.9 g/mol
PubChem CID
139035031
KPVThree-amino-acid peptide · Skin researchPreclinical literature 6 key studiesResearch & sources

KPV is the tripeptide lysine-proline-valine, the C-terminal end of alpha-MSH. It is studied in cell and mouse models of inflammation, especially colitis.

Research summary
Published work is preclinical: colitis models in mice, skin and macrophage cell studies, and new oral delivery systems. No completed human trial was found.
Evidence limits
Cell and animal findings are not human outcome evidence.
U.S. status · November 7, 2026
FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 8–6, one abstention). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.
Read the full KPV reference →Send research request →
Identity & technical details
Primary name
KPV
Also indexed as
Lys-Pro-Val / Lysine-proline-valine
Sequence
Lys-Pro-Val
Molecular formula
C16H30N4O4
Molecular mass
342.43 g/mol
PubChem CID
125672
BPC-157Skin, tendon & connective-tissue modelsPreclinical literature / FDA review 8 key studiesResearch & sources

BPC-157 is a synthetic 15-residue peptide studied mostly in rodent models of tissue and gut injury. In 2026 it moved from FDA’s restricted list to an HHS interim compounding policy, though it remains unapproved.

Research summary
The record is mainly preclinical. Human data are limited to small case series; two 2026 systematic reviews and an orthopaedic review conclude that controlled human evidence is lacking.
Evidence limits
Preclinical findings do not establish human effectiveness or safety, and evidence for one compound does not transfer to a blend.
U.S. status · November 7, 2026
FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 8–6, one abstention; nominated for ulcerative colitis). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.
Read the full BPC-157 reference →Send research request →
Identity & technical details
Primary name
BPC-157
Also indexed as
Body protection compound 157
Molecular formula
C62H98N16O22
Molecular mass
1419.5 g/mol
PubChem CID
9941957
TB-500Peptide fragment · Cell movement & tissue modelsIdentity review required 6 key studiesResearch & sources

FDA defines TB-500 as the seven-residue thymosin beta-4 fragment LKKTETQ with N-terminal acetylation. It is not full-length thymosin beta-4, and most published research is on the full-length protein.

Research summary
Human trials studied full-length thymosin beta-4 (for example in venous ulcers). FDA reported finding no published in-vivo wound studies for the defined fragment itself.
Evidence limits
Full-length thymosin beta-4 evidence cannot be assigned to TB-500 without exact structural documentation.
U.S. status · November 7, 2026
FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 8–6, one abstention; the nominated substance was the fragment). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.
Read the full TB-500 reference →Send research request →
Identity & technical details
Primary name
TB-500
Also indexed as
N-acetyl-LKKTETQ / Thymosin beta-4 fragment 17-23
Sequence
N-acetyl-LKKTETQ
GLOWBPC-157 + GHK-Cu + TB-500Component sources only 3 componentsResearch & sources

GLOW is a blend name for BPC-157 + GHK-Cu + TB-500. It has no single molecular identity; each component has its own reference and evidence record.

Research summary
No study of this exact combination was found. Read each component’s key studies separately.
Evidence limits
Evidence for one component does not establish the stability, compatibility, safety or performance of the mixture.
U.S. status · November 7, 2026
FDA’s 2026 advisory review evaluated single substances only. No mixture was evaluated, and component evidence does not establish how a blend behaves.
Read the full GLOW reference →Send research request →
Identity & technical details
Primary name
GLOW
Also indexed as
GLO / BPC-157 + GHK-Cu + TB-500 / Body Protection Complex / Three-component source-list group
Components
BPC-157 + GHK-Cu + TB-500
KLOWGHK-Cu + TB-500 + BPC-157 + KPVComponent sources only 4 componentsResearch & sources

KLOW is a blend name for GHK-Cu + TB-500 + BPC-157 + KPV. It has no single molecular identity; each component has its own reference and evidence record.

Research summary
No study of this exact combination was found. Read each component’s key studies separately.
Evidence limits
Evidence for one component does not establish the stability, compatibility, safety or performance of the mixture.
U.S. status · November 7, 2026
FDA’s 2026 advisory review evaluated single substances only. No mixture was evaluated, and component evidence does not establish how a blend behaves.
Read the full KLOW reference →Send research request →
Identity & technical details
Primary name
KLOW
Also indexed as
GHK-Cu + TB-500 + BPC-157 + KPV / KLOW source-list label
Components
GHK-Cu + TB-500 + BPC-157 + KPV
WolverineBPC-157 + TB-500Component sources only 2 componentsResearch & sources

Wolverine is a blend name for BPC-157 + TB-500. It has no single molecular identity; each component has its own reference and evidence record.

Research summary
No study of this exact combination was found. Read each component’s key studies separately.
Evidence limits
Evidence for one component does not establish the stability, compatibility, safety or performance of the mixture.
U.S. status · November 7, 2026
FDA’s 2026 advisory review evaluated single substances only. No mixture was evaluated, and component evidence does not establish how a blend behaves.
Read the full Wolverine reference →Send research request →
Identity & technical details
Primary name
Wolverine
Also indexed as
BPC-157 + TB-500 / Wolverine stack / Two-component source-list group
Components
BPC-157 + TB-500

Components

KPV + GHK-CuKPV + GHK-CuComponent sources only 2 componentsResearch & sources

KPV + GHK-Cu is a blend name for KPV + GHK-Cu. It has no single molecular identity; each component has its own reference and evidence record.

Research summary
No study of this exact combination was found. Read each component’s key studies separately.
Evidence limits
Evidence for one component does not establish the stability, compatibility, safety or performance of the mixture.
U.S. status · November 7, 2026
FDA’s 2026 advisory review evaluated single substances only. No mixture was evaluated, and component evidence does not establish how a blend behaves.
Read the full KPV + GHK-Cu reference →Send research request →
Identity & technical details
Primary name
KPV + GHK-Cu
Also indexed as
Two-component source-list group
Components
KPV + GHK-Cu

Components

HCGReproductive hormone researchFDA-labeled biologic reference 2 key studiesResearch & sources

Human chorionic gonadotropin (hCG) is a glycoprotein hormone with alpha and beta subunits. FDA-labeled hCG products state potency in USP units rather than by mass.

Research summary
The literature spans reproductive endocrinology, diagnostics and pharmacology. Recent human work compares recombinant and urinary hCG.
Evidence limits
Mass alone does not establish hCG potency or equivalence between products.
U.S. status · November 7, 2026
FDA-labeled hCG drug products exist and are dosed in USP units. This reference does not describe or imply any Elevated Pharma product.
Read the full HCG reference →Send research request →
Identity & technical details
Primary name
HCG
Also indexed as
Human chorionic gonadotropin / hCG
GHRP-2Growth-hormone pathway researchHuman research literature 6 key studiesResearch & sources

GHRP-2 (pralmorelin) is a synthetic hexapeptide growth-hormone secretagogue. It has been used as a diagnostic test agent in Japan and studied in human endocrine research.

Research summary
Human studies cover pharmacokinetics in children, GH release in critical illness and diagnostic testing of the pituitary.
Evidence limits
Endocrine response data do not provide a general safety conclusion or establish an independently sourced material’s identity.
U.S. status · November 7, 2026
Not FDA-approved. GHRP-2 was not on FDA’s 2026 compounding advisory agendas.
Read the full GHRP-2 reference →Send research request →
Identity & technical details
Primary name
GHRP-2
Also indexed as
Growth hormone-releasing peptide 2 / Pralmorelin
Molecular formula
C45H55N9O6
Molecular mass
818 g/mol
PubChem CID
6918245
TesamorelinGrowth-hormone pathway researchFDA-labeled drug reference 6 key studiesResearch & sources

Tesamorelin is a stabilized analog of growth-hormone-releasing hormone and the active ingredient in FDA-approved Egrifta, used for excess abdominal fat in people with HIV.

Research summary
Randomized trials in people with HIV cover visceral fat, fatty liver and neurocognition; smaller studies examine people without HIV.
Evidence limits
Approval of a prescription product does not transfer to an unlabeled research material.
U.S. status · November 7, 2026
FDA-approved as Egrifta SV and Egrifta WR for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Prescribing information is the controlling source.
Read the full Tesamorelin reference →Send research request →
Identity & technical details
Primary name
Tesamorelin
Also indexed as
TH9507
Molecular formula
C221H366N72O67S
Molecular mass
5136 g/mol
PubChem CID
16137828
IpamorelinGrowth-hormone pathway researchHuman research literature 5 key studiesResearch & sources

Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue, first described in 1998 as selective for growth hormone release.

Research summary
Human data are limited to pharmacokinetic modeling in volunteers and one phase 2 trial in postoperative ileus.
Evidence limits
A small clinical literature does not establish broad safety or effectiveness.
U.S. status · November 7, 2026
Not FDA-approved. Ipamorelin was not on FDA’s 2026 compounding advisory agendas.
Read the full Ipamorelin reference →Send research request →
Identity & technical details
Primary name
Ipamorelin
Also indexed as
NNC 26-0161
Molecular formula
C38H49N9O5
Molecular mass
711.9 g/mol
PubChem CID
9831659
SermorelinGrowth-hormone pathway researchHuman research literature 5 key studiesResearch & sources

Sermorelin is a synthetic 29-residue analog of the active end of growth-hormone-releasing hormone, GHRH(1-29). It was previously marketed in the U.S. as Geref.

Research summary
Human endocrine studies used GHRH(1-29) to test pituitary growth-hormone response; recent literature focuses on detection methods and sports use.
Evidence limits
A base-compound record does not establish acetate content, purity or potency of a specific material.
U.S. status · November 7, 2026
No current FDA-approved sermorelin product is marketed. It was not on FDA’s 2026 compounding advisory agendas.
Read the full Sermorelin reference →Send research request →
Identity & technical details
Primary name
Sermorelin
Also indexed as
Sermorelin acetate / GHRH(1-29) analog
Molecular formula
C149H246N44O42S
Molecular mass
3357.9 g/mol
PubChem CID
16132413
SelankNervous-system & cognition researchPreclinical and analytical literature 6 key studiesResearch & sources

Selank is a synthetic heptapeptide based on tuftsin. Most of its literature comes from Russian research groups, with a few small clinical studies in anxiety.

Research summary
Animal work covers anxiety, stress and memory models; small Russian clinical studies examine anxiety disorders.
Evidence limits
Small, mostly non-Western studies do not establish human safety or effectiveness by current standards.
U.S. status · November 7, 2026
Not FDA-approved. Selank was not on FDA’s 2026 compounding advisory agendas.
Read the full Selank reference →Send research request →
Identity & technical details
Primary name
Selank
Also indexed as
Thr-Lys-Pro-Arg-Pro-Gly-Pro
Sequence
Thr-Lys-Pro-Arg-Pro-Gly-Pro
Molecular formula
C33H57N11O9
Molecular mass
751.9 g/mol
PubChem CID
11765600
SemaxNervous-system & cognition researchPreclinical and analytical literature 6 key studiesResearch & sources

Semax is a synthetic heptapeptide derived from ACTH(4-10). It is registered as a medicine in Russia and studied mainly in stroke and nervous-system models.

Research summary
Animal studies cover stroke, spinal cord injury and Alzheimer’s models; Russian clinical studies examine stroke recovery but are mostly not placebo-controlled.
Evidence limits
The cited research does not establish an FDA-approved use or a human safety conclusion.
U.S. status · November 7, 2026
FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 24, 2026 (recommended). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.
Read the full Semax reference →Send research request →
Identity & technical details
Primary name
Semax
Also indexed as
Met-Glu-His-Phe-Pro-Gly-Pro
Sequence
Met-Glu-His-Phe-Pro-Gly-Pro
Molecular formula
C37H51N9O10S
Molecular mass
813.9 g/mol
PubChem CID
9811102
DSIPSleep-related peptide researchLimited human literature 4 key studiesResearch & sources

Delta sleep-inducing peptide (DSIP, emideltide) is a nonapeptide isolated in the 1970s. Small human sleep studies from the 1980s and 1990s reported mixed results.

Research summary
Early isolation work defined the sequence; small clinical studies in insomnia found weak or inconsistent effects.
Evidence limits
The limited, mixed human literature does not establish benefit or safety.
U.S. status · November 7, 2026
FDA’s compounding advisory committee voted 7–6 (one abstention) against adding emideltide (DSIP) to the 503A bulks list on July 24, 2026, the only one of seven peptides it turned down. It is not covered by the October 2026 HHS interim policy.
Read the full DSIP reference →Send research request →
Identity & technical details
Primary name
DSIP
Also indexed as
Delta sleep-inducing peptide / DSIP / Emideltide
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Molecular formula
C35H48N10O15
Molecular mass
848.8 g/mol
PubChem CID
68816
EpitalonCellular aging researchPreclinical literature 6 key studiesResearch & sources

Epitalon (also spelled epithalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, studied in aging models. Most of its literature comes from one Russian research network.

Research summary
Work covers telomerase activity in cell lines, animal aging and cancer models, and small Russian human studies. A 2025 independent study replicated telomere effects in human cell lines.
Evidence limits
Cell and animal findings do not establish human longevity or clinical benefit.
U.S. status · November 7, 2026
FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 24, 2026 (recommended). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.
Read the full Epitalon reference →Send research request →
Identity & technical details
Primary name
Epitalon
Also indexed as
Epithalon / Ala-Glu-Asp-Gly
Sequence
Ala-Glu-Asp-Gly
Molecular formula
C14H22N4O9
Molecular mass
390.35 g/mol
PubChem CID
219042
ThymalinThymus-derived material · Immune researchIdentity review required 4 key studiesResearch & sources

Thymalin is a peptide complex originally extracted from calf thymus and used in Russia. It is not one fixed molecule, so composition must be documented case by case.

Research summary
Russian clinical and laboratory studies span immunology and aging; recent work is in cell models.
Evidence limits
A label reading only “Thymalin” does not establish composition or equivalence to a literature preparation.
U.S. status · November 7, 2026
Not FDA-approved. No approved-product or permitted-use claim is made.
Read the full Thymalin reference →Send research request →
Identity & technical details
Primary name
Thymalin
Also indexed as
Thymalin peptide complex
MOTS-cMitochondrial-derived peptide · Cellular energy researchPreclinical literature 6 key studiesResearch & sources

MOTS-c is a 16-residue peptide encoded in mitochondrial DNA. It was first described in 2015 and is studied in cell and animal models of metabolism and exercise.

Research summary
Most work is in cells and mice. Human studies so far measure natural MOTS-c levels in blood, for example after exercise; they do not test MOTS-c given as a drug.
Evidence limits
Preclinical findings do not establish human safety, clinical effectiveness or a material specification.
U.S. status · November 7, 2026
FDA removed it from its Category 2 compounding list in April 2026, and FDA’s compounding advisory committee recommended it for the 503A bulks list on July 23, 2026 (vote 7–5, two abstentions). On October 28, 2026, HHS issued an interim policy saying it will not take enforcement action against licensed pharmacies and physicians that compound it under listed conditions, such as FDA-registered sourcing, a certificate of analysis and safety reporting. It is not FDA-approved, and the policy does not cover research-use-only material.
Read the full MOTS-c reference →Send research request →
Identity & technical details
Primary name
MOTS-c
Also indexed as
Mitochondrial open reading frame of the 12S rRNA-c
Sequence
MRWQEMGYIFYPRKLR
Molecular formula
C101H152N28O22S2
Molecular mass
2174.6 g/mol
PubChem CID
146675088
NAD+Cellular energy coenzyme · Not a peptideBiochemical reference 6 key studiesResearch & sources

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme in cellular energy and redox reactions, not a peptide. Most human research tests its precursors, NR and NMN.

Research summary
Human randomized trials of NR and NMN measure blood NAD+ and metabolic markers. A 2026 Nature Metabolism study compared three precursors head to head.
Evidence limits
Raising blood NAD+ is not the same as a clinical benefit, and precursor studies do not describe NAD+ itself given directly.
U.S. status · November 7, 2026
No therapeutic or approved-product claim is made.
Read the full NAD+ reference →Send research request →
Identity & technical details
Primary name
NAD+
Also indexed as
Nicotinamide adenine dinucleotide / NAD / Nadide
PubChem CID
5892